AnalysisNews

BCAX today

$10.53+$0.35 (+3.44%)close Nov 11, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bullish

1 hourLeaning Bearish

15 minStrong Bearish

5 minStrong Bearish

Daily trend turns up above $18.78

Key levels

Resistance$13.75

Resistance$12.30

Support$10.29

Support$7.87

Latest news & SEC filings

AnalystNov 11, 2026Analyst Firm Keeps Positive Stance on Bicara Therapeutics

AnalystNov 11, 2026Morgan Stanley starts Bicara Therapeutics coverage with Buy rating

AnalystNov 11, 2026HC Wainwright keeps Buy rating on Bicara Therapeutics, cuts price target to $36

AnalystNov 10, 2026Morgan Stanley keeps Overweight on Bicara Therapeutics, cuts target to $30

All BCAX news →

About Bicara Therapeutics

Bicara Therapeutics develops bifunctional medicines aimed at solid tumors. Its main candidate, ficerafusp alfa, pairs an EGFR-targeting antibody with a TGF-beta trap and is being tested in squamous cancers of the head, neck and other sites, given by itself and alongside pembrolizumab. The company carries out its work in the United States and Canada.

Based on the company's 10-K filed Mar 30, 2026.

Nasdaq · Healthcare

Bicara Therapeutics Inc. (BCAX)

$10.53+0.35 (+3.44%)
WATCHLISTGrade: BRisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
10.0112.1014.1816.2710.53Oct 9Oct 19Oct 27Nov 4
High11.45
Low10.11
Open10.34
Volume1.49M
Avg Vol1.69M
VWAP10.82
30d High18.35
30d Low7.93
30d Chg-42.14%
See full chart with real-time data

What Is the Price Target for BCAX?

SEPT Low Target

$8.00

SEPT Mid Target

$35.00

SEPT High Target

$43.00

Analyst Consensus

$35.00

Current: $10.53Upside: +232.4%Confidence: 85%Method: Analyst Consensus

Is BCAX a Buy or Sell Right Now?

58
Investability Score
WATCHLIST12-18 months
News summary · last 30 days
Nov 11▲ UpUpgrade2 articles
Bicara Therapeutics shares closed at $10.53, up 1.74% on volume of 1,488,974, after Morgan Stanley initiated coverage with a Buy rating. HC Wainwright also maintained its Buy rating but lowered its price target to $36, a neutral update that still implies significant upside from the current price. The stock traded in a wide range of $10.11 to $11.45 during the session. Overall, the analyst actions, particularly the new Buy rating from Morgan Stanley, provided a bullish signal for the stock.
Nov 9▲ UpEarningsProduct4 articles
Bicara Therapeutics shares surged 12.13% to close at $9.98 after the company provided a business update alongside its Q3 2026 earnings call. The stock's rally came despite the company reporting a wider-than-expected quarterly loss of $1.04 per share versus the $0.81 consensus estimate. The positive momentum was driven by news that the registrational FORTIFI-HN01 study is fully recruiting, with interim data expected in mid-2027. The strong patient accrual in this head and neck cancer trial appears to have overshadowed the earnings miss, signaling investor optimism about the pipeline's progress.

Thesis

  • •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BCAX.

Start Free Trial →

Is BCAX Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

P/B, Analyst Consensus

Fair Value

$30.66

12

Moat Score

NONE

1/9

Piotroski Score

11303.5

Altman Z-Score

What Is Smart Money Doing with BCAX?

Insider Signal

SELLING

0 buys / 10 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Recent Insider Activity

NameTitleTypeSharesValueDate
Hyep IvanofficerBuy9,200$35KMay 21, 2026
Hyep IvanofficerSale9,200$188KMay 21, 2026
Mazumdar Clairedirector officerBuy15,000$57KMay 18, 2026
Mazumdar Clairedirector officerSale12,022$240KMay 18, 2026
Mazumdar Clairedirector officerSale2,978$61KMay 18, 2026
Cohlhepp Ryandirector officerBuy8,000$30KMay 15, 2026
Cohlhepp Ryandirector officerSale8,000$162KMay 15, 2026
Cohlhepp Ryandirector officerSale4,500$91KMay 15, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

BCAX Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

37.78%

FCF Growth YoY

-43.2%

Revenue Trend

UNKNOWN

Dark Pool Trades for BCAX

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for BCAX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
21:00:22$10.532,564$$27KBUY
21:00:22$10.532,130$$22KBUY
21:00:21$10.531,039$$11KBUY
21:00:21$10.533,400$$36KBUY
21:00:01$10.531,300$$14KBUY

5 dark pool trades shown · $$110K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Bicara Therapeutics Inc. (BCAX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

BCAX — frequently asked questions

What is BCAX stock price today?

Bicara Therapeutics Inc. (BCAX) is at $10.53, up 3.44% (+$0.35) at the Nov 11, 2026 close.

Why is BCAX stock up today?

Nov 11, 2026: Bicara Therapeutics shares closed at $10.53, up 1.74% on volume of 1,488,974, after Morgan Stanley initiated coverage with a Buy rating. HC Wainwright also maintained its Buy rating but lowered its price target to $36, a neutral update that still implies significant upside from the current price.

What is the BCAX price target?

The average analyst price target for BCAX is $35.00, ranging from $8 to $43, based on 11 analysts. Latest: HC Wainwright & Co. maintains on Nov 11, 2026.

What do analysts rate BCAX?

Analyst ratings for BCAX: 0 Buy, 19 Hold, 2 Sell — consensus Hold.

Did BCAX beat earnings?

BCAX last reported on Nov 9, 2026: EPS -$1.04 vs -$0.81 expected — a miss of 28.4%.

Does BCAX pay a dividend?

BCAX does not currently pay a dividend.

What are BCAX support and resistance levels?

Support: $10.29, $7.87. Resistance: $12.30, $13.75, $16.60.

What are insiders doing with BCAX?

Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.

What is the latest news on BCAX?

Nov 11, 2026: Analyst Firm Keeps Positive Stance on Bicara Therapeutics · Nov 11, 2026: Morgan Stanley starts Bicara Therapeutics coverage with Buy rating · Nov 11, 2026: HC Wainwright keeps Buy rating on Bicara Therapeutics, cuts price target to $36